Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts

Michele Bortolomeazzi; Mohamed Reda Keddar; Lucia Montorsi; Amelia Acha-sagredo; Lorena Benedetti; Damjan Temelkovski; Subin Choi; Nedyalko Petrov; Katrina Todd; Patty Wai; Jonny Kohl; Tamara Denner; Emma Nye; Robert Goldstone; Sophia Ward; Gareth A. Wilson; Maise Al Bakir; Charles Swanton; Susan John; James Miles; Banafshe Larijani; Victoria Kunene; Elisa Fontana; Hendrik-tobias Arkenau; Peter J. Parker; Manuel Rodriguez-justo; Kai-keen Shiu; Jo Spencer; Francesca D. Ciccarelli

doi:10.1053/j.gastro.2021.06.064

Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts

Michele Bortolomeazzi, Mohamed Reda Keddar, Lucia Montorsi, Amelia Acha-sagredo, Lorena Benedetti, Damjan Temelkovski, Subin Choi, Nedyalko Petrov, Katrina Todd, Patty Wai, Jonny Kohl, Tamara Denner, Emma Nye, Robert Goldstone, Sophia Ward, Gareth A. Wilson, Maise Al Bakir, Charles Swanton, Susan John, James MilesBanafshe Larijani, Victoria Kunene, Elisa Fontana, Hendrik-tobias Arkenau, Peter J. Parker, Manuel Rodriguez-justo, Kai-keen Shiu, Jo Spencer, Francesca D. Ciccarelli

Research output: Contribution to journal › Article › peer-review

82 Citations (Scopus)

Abstract

Background & Aims: Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumor mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumor microenvironment (TME) from patients treated with pembrolizumab (KEYNOTE 177 clinical trial) or nivolumab to dissect the cellular and molecular determinants of response to anti- programmed cell death 1 (PD1) immunotherapy. Methods: We selected multiple regions per tumor showing variable T-cell infiltration for a total of 738 regions from 29 patients, divided into discovery and validation cohorts. We performed multiregional whole-exome and RNA sequencing of the tumor cells and integrated these with T-cell receptor sequencing, high-dimensional imaging mass cytometry, detection of programmed death-ligand 1 (PDL1) interaction in situ, multiplexed immunofluorescence, and computational spatial analysis of the TME. Results: In hypermutated CRCs, response to anti-PD1 immunotherapy was not associated with TMB but with high clonality of immunogenic mutations, clonally expanded T cells, low activation of Wnt signaling, deregulation of the interferon gamma pathway, and active immune escape mechanisms. Responsive hypermutated CRCs were also rich in cytotoxic and proliferating PD1 ⁺CD8 T cells interacting with PDL1 ⁺ antigen-presenting macrophages. Conclusions: Our study clarified the limits of TMB as a predictor of response of CRC to anti-PD1 immunotherapy. It identified a population of antigen-presenting macrophages interacting with CD8 T cells that consistently segregate with response. We therefore concluded that anti-PD1 agents release the PD1-PDL1 interaction between CD8 T cells and macrophages to promote cytotoxic antitumor activity.

Original language	English
Pages (from-to)	1179-1193
Number of pages	15
Journal	Gastroenterology
Volume	161
Issue number	4
Early online date	28 Jun 2021
DOIs	https://doi.org/10.1053/j.gastro.2021.06.064
Publication status	Published - Oct 2021

Keywords

Colorectal cancer
anti-PD1 immunothrepy
Tumour Mutational Burder
Wnt signalling
Interferon Gamma
CD8 T cells
Antigen Presenting Macrophages
Keynote177

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1053/j.gastro.2021.06.064Licence: CC BY

Cite this

Bortolomeazzi, M., Keddar, M. R., Montorsi, L., Acha-sagredo, A., Benedetti, L., Temelkovski, D., Choi, S., Petrov, N., Todd, K., Wai, P., Kohl, J., Denner, T., Nye, E., Goldstone, R., Ward, S., Wilson, G. A., Al Bakir, M., Swanton, C., John, S., ... Ciccarelli, F. D. (2021). Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts. Gastroenterology, 161(4), 1179-1193. https://doi.org/10.1053/j.gastro.2021.06.064

@article{6bb276aa5f9c4710bb0bb51fd37f728b,

title = "Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts",

abstract = "Background & Aims: Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumor mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumor microenvironment (TME) from patients treated with pembrolizumab (KEYNOTE 177 clinical trial) or nivolumab to dissect the cellular and molecular determinants of response to anti- programmed cell death 1 (PD1) immunotherapy. Methods: We selected multiple regions per tumor showing variable T-cell infiltration for a total of 738 regions from 29 patients, divided into discovery and validation cohorts. We performed multiregional whole-exome and RNA sequencing of the tumor cells and integrated these with T-cell receptor sequencing, high-dimensional imaging mass cytometry, detection of programmed death-ligand 1 (PDL1) interaction in situ, multiplexed immunofluorescence, and computational spatial analysis of the TME. Results: In hypermutated CRCs, response to anti-PD1 immunotherapy was not associated with TMB but with high clonality of immunogenic mutations, clonally expanded T cells, low activation of Wnt signaling, deregulation of the interferon gamma pathway, and active immune escape mechanisms. Responsive hypermutated CRCs were also rich in cytotoxic and proliferating PD1 +CD8 T cells interacting with PDL1 + antigen-presenting macrophages. Conclusions: Our study clarified the limits of TMB as a predictor of response of CRC to anti-PD1 immunotherapy. It identified a population of antigen-presenting macrophages interacting with CD8 T cells that consistently segregate with response. We therefore concluded that anti-PD1 agents release the PD1-PDL1 interaction between CD8 T cells and macrophages to promote cytotoxic antitumor activity. ",

keywords = "Colorectal cancer, anti-PD1 immunothrepy, Tumour Mutational Burder, Wnt signalling, Interferon Gamma, CD8 T cells, Antigen Presenting Macrophages, Keynote177",

author = "Michele Bortolomeazzi and Keddar, {Mohamed Reda} and Lucia Montorsi and Amelia Acha-sagredo and Lorena Benedetti and Damjan Temelkovski and Subin Choi and Nedyalko Petrov and Katrina Todd and Patty Wai and Jonny Kohl and Tamara Denner and Emma Nye and Robert Goldstone and Sophia Ward and Wilson, {Gareth A.} and {Al Bakir}, Maise and Charles Swanton and Susan John and James Miles and Banafshe Larijani and Victoria Kunene and Elisa Fontana and Hendrik-tobias Arkenau and Parker, {Peter J.} and Manuel Rodriguez-justo and Kai-keen Shiu and Jo Spencer and Ciccarelli, {Francesca D.}",

note = "Funding Information: Funding This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001002, FC001169, FC001745, FC001130), the UK Medical Research Council (FC001002, FC001169, FC001745, FC001130), and the Wellcome Trust (FC001002, FC001169, FC001745, FC001130). Francesca D. Ciccarelli is supported by Cancer Research UK (C43634/A25487), Guys and St Thomas Charity (R170504), the European Union{\textquoteright}s Horizon 2020 Research and Innovation programme under the Marie Sk{\l}odowska-Curie grant agreement No. CONTRA-766030, the Cancer Research UK King{\textquoteright}s Health Partners Centre at King{\textquoteright}s College London (C604/A25135), and the Cancer Research UK City of London Centre (C7893/A26233). Funding Information: The authors thank Professor Rebecca Fitzgerald (University of Cambridge) and Professor Toby Lawrence (King{\textquoteright}s College London) for critical comments to the manuscript. The authors acknowledge technical support from the Advanced Sequencing, the Flow Cytometry and the Experimental Histopathology Platforms of The Francis Crick Institute, the National Institute for Health Research Biomedical Research Centre Immune Monitoring Core Facility Centre based at Guy{\textquoteright}s and St Thomas{\textquoteright} National Health Service Foundation Trust and King{\textquoteright}s College London, Christopher Applebee and S{\'a}nchez-Magraner for the FRET analysis, and Joe Brock for graphical illustrations. The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the United Kingdom Department of Health. The results published here are in part based upon data generated by The Cancer Genome Atlas managed by the National Cancer Institute and National Human Genome Research Institute. WES (EGAD00001006165) and RNA sequencing (EGAD00001006164) data have been deposited in the European Genome-phenome Archive. TCR-seq ( https://doi.org/10.5281/zenodo.3744371 ) and IMC ( https://doi.org/10.5281/zenodo.3743253 ) data have been deposited in Zenodo. The code used in this study and all supporting data are available upon request. Funding Information: The authors thank Professor Rebecca Fitzgerald (University of Cambridge) and Professor Toby Lawrence (King's College London) for critical comments to the manuscript. The authors acknowledge technical support from the Advanced Sequencing, the Flow Cytometry and the Experimental Histopathology Platforms of The Francis Crick Institute, the National Institute for Health Research Biomedical Research Centre Immune Monitoring Core Facility Centre based at Guy's and St Thomas? National Health Service Foundation Trust and King's College London, Christopher Applebee and S?nchez-Magraner for the FRET analysis, and Joe Brock for graphical illustrations. The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the United Kingdom Department of Health. The results published here are in part based upon data generated by The Cancer Genome Atlas managed by the National Cancer Institute and National Human Genome Research Institute. WES (EGAD00001006165) and RNA sequencing (EGAD00001006164) data have been deposited in the European Genome-phenome Archive. TCR-seq (https://doi.org/10.5281/zenodo.3744371) and IMC (https://doi.org/10.5281/zenodo.3743253) data have been deposited in Zenodo. The code used in this study and all supporting data are available upon request. Michele Bertolomeazzi, MRes (Formal analysis: Equal; Software: Lead; Writing ? original draft: Equal). Reda Keddar, MRes (Formal analysis: Equal; Methodology: Lead; Writing ? original draft: Supporting). Lucia Montorsi, PhD (Data curation: Equal; Formal analysis: Equal; Writing ? original draft: Supporting). Amelia Acha, PhD (Data curation: Equal; Formal analysis: Equal; Writing ? original draft: Supporting). Lorena Benedetti, PhD (Data curation: Supporting; Formal analysis: Supporting). Damjan Temelkowski, PhD (Methodology: Supporting; Software: Supporting). Subin Choi, MRes (Data curation: Supporting). Nedyalko Petrov, MRes (Methodology: Supporting). Katrina Todd, PhD (Methodology: Supporting). Patty Way, PhD (Methodology: Supporting). Jonny Kohl, PhD (Methodology: Supporting). Tamara Denner, PhD (Methodology: Supporting). Emma Nye, PhD (Methodology: Supporting). Robert Goldstone, PhD (Methodology: Supporting). Sophia Ward, PhD (Methodology: Supporting). Gareth Wilson, PhD (Methodology: Supporting). Maise Al Bakir, PhD (Methodology: Supporting). Charles Swanton, PhD (Methodology: Supporting). Susan John, PhD (Formal analysis: Supporting). James Miles, MRes (Methodology: Supporting). Banafshe Larijani, PhD (Methodology: Supporting). Victoria Kunene, PhD (Resources: Supporting). Elisa Fontana, PhD (Resources: Supporting). Toby Arkenau, PhD (Resources: Supporting). Peter Parker, PhD (Methodology: Supporting). Manuel Rodriguez-Justo, PhD (Formal analysis: Supporting; Investigation: Supporting; Resources: Lead; Writing ? original draft: Supporting). Kai-Keen Shiu, MD PhD (Investigation: Supporting; Resources: Lead; Writing ? original draft: Supporting). Jo Spencer, PhD (Conceptualization: Equal; Formal analysis: Equal; Writing ? original draft: Equal). Francesca Ciccarelli, PhD (Conceptualization: Equal; Funding acquisition: Lead; Investigation: Lead; Supervision: Lead; Writing ? original draft: Equal). Funding This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001002, FC001169, FC001745, FC001130), the UK Medical Research Council (FC001002, FC001169, FC001745, FC001130), and the Wellcome Trust (FC001002, FC001169, FC001745, FC001130). Francesca D. Ciccarelli is supported by Cancer Research UK (C43634/A25487), Guys and St Thomas Charity (R170504), the European Union's Horizon 2020 Research and Innovation programme under the Marie Sk?odowska-Curie grant agreement No. CONTRA-766030, the Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135), and the Cancer Research UK City of London Centre (C7893/A26233). Publisher Copyright: {\textcopyright} 2021 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = oct,

doi = "10.1053/j.gastro.2021.06.064",

language = "English",

volume = "161",

pages = "1179--1193",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "WB Saunders",

number = "4",

}

Bortolomeazzi, M , Keddar, MR , Montorsi, L , Acha-sagredo, A , Benedetti, L , Temelkovski, D , Choi, S, Petrov, N, Todd, K, Wai, P, Kohl, J, Denner, T, Nye, E, Goldstone, R, Ward, S, Wilson, GA, Al Bakir, M, Swanton, C, John, S, Miles, J, Larijani, B, Kunene, V, Fontana, E, Arkenau, H, Parker, PJ, Rodriguez-justo, M, Shiu, K, Spencer, J & Ciccarelli, FD 2021, 'Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts', Gastroenterology, vol. 161, no. 4, pp. 1179-1193. https://doi.org/10.1053/j.gastro.2021.06.064

TY - JOUR

T1 - Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts

AU - Bortolomeazzi, Michele

AU - Keddar, Mohamed Reda

AU - Montorsi, Lucia

AU - Acha-sagredo, Amelia

AU - Benedetti, Lorena

AU - Temelkovski, Damjan

AU - Choi, Subin

AU - Petrov, Nedyalko

AU - Todd, Katrina

AU - Wai, Patty

AU - Kohl, Jonny

AU - Denner, Tamara

AU - Nye, Emma

AU - Goldstone, Robert

AU - Ward, Sophia

AU - Wilson, Gareth A.

AU - Al Bakir, Maise

AU - Swanton, Charles

AU - John, Susan

AU - Miles, James

AU - Larijani, Banafshe

AU - Kunene, Victoria

AU - Fontana, Elisa

AU - Arkenau, Hendrik-tobias

AU - Parker, Peter J.

AU - Rodriguez-justo, Manuel

AU - Shiu, Kai-keen

AU - Spencer, Jo

AU - Ciccarelli, Francesca D.

N1 - Funding Information: Funding This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001002, FC001169, FC001745, FC001130), the UK Medical Research Council (FC001002, FC001169, FC001745, FC001130), and the Wellcome Trust (FC001002, FC001169, FC001745, FC001130). Francesca D. Ciccarelli is supported by Cancer Research UK (C43634/A25487), Guys and St Thomas Charity (R170504), the European Union’s Horizon 2020 Research and Innovation programme under the Marie Skłodowska-Curie grant agreement No. CONTRA-766030, the Cancer Research UK King’s Health Partners Centre at King’s College London (C604/A25135), and the Cancer Research UK City of London Centre (C7893/A26233). Funding Information: The authors thank Professor Rebecca Fitzgerald (University of Cambridge) and Professor Toby Lawrence (King’s College London) for critical comments to the manuscript. The authors acknowledge technical support from the Advanced Sequencing, the Flow Cytometry and the Experimental Histopathology Platforms of The Francis Crick Institute, the National Institute for Health Research Biomedical Research Centre Immune Monitoring Core Facility Centre based at Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College London, Christopher Applebee and Sánchez-Magraner for the FRET analysis, and Joe Brock for graphical illustrations. The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the United Kingdom Department of Health. The results published here are in part based upon data generated by The Cancer Genome Atlas managed by the National Cancer Institute and National Human Genome Research Institute. WES (EGAD00001006165) and RNA sequencing (EGAD00001006164) data have been deposited in the European Genome-phenome Archive. TCR-seq ( https://doi.org/10.5281/zenodo.3744371 ) and IMC ( https://doi.org/10.5281/zenodo.3743253 ) data have been deposited in Zenodo. The code used in this study and all supporting data are available upon request. Funding Information: The authors thank Professor Rebecca Fitzgerald (University of Cambridge) and Professor Toby Lawrence (King's College London) for critical comments to the manuscript. The authors acknowledge technical support from the Advanced Sequencing, the Flow Cytometry and the Experimental Histopathology Platforms of The Francis Crick Institute, the National Institute for Health Research Biomedical Research Centre Immune Monitoring Core Facility Centre based at Guy's and St Thomas? National Health Service Foundation Trust and King's College London, Christopher Applebee and S?nchez-Magraner for the FRET analysis, and Joe Brock for graphical illustrations. The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the United Kingdom Department of Health. The results published here are in part based upon data generated by The Cancer Genome Atlas managed by the National Cancer Institute and National Human Genome Research Institute. WES (EGAD00001006165) and RNA sequencing (EGAD00001006164) data have been deposited in the European Genome-phenome Archive. TCR-seq (https://doi.org/10.5281/zenodo.3744371) and IMC (https://doi.org/10.5281/zenodo.3743253) data have been deposited in Zenodo. The code used in this study and all supporting data are available upon request. Michele Bertolomeazzi, MRes (Formal analysis: Equal; Software: Lead; Writing ? original draft: Equal). Reda Keddar, MRes (Formal analysis: Equal; Methodology: Lead; Writing ? original draft: Supporting). Lucia Montorsi, PhD (Data curation: Equal; Formal analysis: Equal; Writing ? original draft: Supporting). Amelia Acha, PhD (Data curation: Equal; Formal analysis: Equal; Writing ? original draft: Supporting). Lorena Benedetti, PhD (Data curation: Supporting; Formal analysis: Supporting). Damjan Temelkowski, PhD (Methodology: Supporting; Software: Supporting). Subin Choi, MRes (Data curation: Supporting). Nedyalko Petrov, MRes (Methodology: Supporting). Katrina Todd, PhD (Methodology: Supporting). Patty Way, PhD (Methodology: Supporting). Jonny Kohl, PhD (Methodology: Supporting). Tamara Denner, PhD (Methodology: Supporting). Emma Nye, PhD (Methodology: Supporting). Robert Goldstone, PhD (Methodology: Supporting). Sophia Ward, PhD (Methodology: Supporting). Gareth Wilson, PhD (Methodology: Supporting). Maise Al Bakir, PhD (Methodology: Supporting). Charles Swanton, PhD (Methodology: Supporting). Susan John, PhD (Formal analysis: Supporting). James Miles, MRes (Methodology: Supporting). Banafshe Larijani, PhD (Methodology: Supporting). Victoria Kunene, PhD (Resources: Supporting). Elisa Fontana, PhD (Resources: Supporting). Toby Arkenau, PhD (Resources: Supporting). Peter Parker, PhD (Methodology: Supporting). Manuel Rodriguez-Justo, PhD (Formal analysis: Supporting; Investigation: Supporting; Resources: Lead; Writing ? original draft: Supporting). Kai-Keen Shiu, MD PhD (Investigation: Supporting; Resources: Lead; Writing ? original draft: Supporting). Jo Spencer, PhD (Conceptualization: Equal; Formal analysis: Equal; Writing ? original draft: Equal). Francesca Ciccarelli, PhD (Conceptualization: Equal; Funding acquisition: Lead; Investigation: Lead; Supervision: Lead; Writing ? original draft: Equal). Funding This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001002, FC001169, FC001745, FC001130), the UK Medical Research Council (FC001002, FC001169, FC001745, FC001130), and the Wellcome Trust (FC001002, FC001169, FC001745, FC001130). Francesca D. Ciccarelli is supported by Cancer Research UK (C43634/A25487), Guys and St Thomas Charity (R170504), the European Union's Horizon 2020 Research and Innovation programme under the Marie Sk?odowska-Curie grant agreement No. CONTRA-766030, the Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135), and the Cancer Research UK City of London Centre (C7893/A26233). Publisher Copyright: © 2021 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/10

Y1 - 2021/10

N2 - Background & Aims: Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumor mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumor microenvironment (TME) from patients treated with pembrolizumab (KEYNOTE 177 clinical trial) or nivolumab to dissect the cellular and molecular determinants of response to anti- programmed cell death 1 (PD1) immunotherapy. Methods: We selected multiple regions per tumor showing variable T-cell infiltration for a total of 738 regions from 29 patients, divided into discovery and validation cohorts. We performed multiregional whole-exome and RNA sequencing of the tumor cells and integrated these with T-cell receptor sequencing, high-dimensional imaging mass cytometry, detection of programmed death-ligand 1 (PDL1) interaction in situ, multiplexed immunofluorescence, and computational spatial analysis of the TME. Results: In hypermutated CRCs, response to anti-PD1 immunotherapy was not associated with TMB but with high clonality of immunogenic mutations, clonally expanded T cells, low activation of Wnt signaling, deregulation of the interferon gamma pathway, and active immune escape mechanisms. Responsive hypermutated CRCs were also rich in cytotoxic and proliferating PD1 +CD8 T cells interacting with PDL1 + antigen-presenting macrophages. Conclusions: Our study clarified the limits of TMB as a predictor of response of CRC to anti-PD1 immunotherapy. It identified a population of antigen-presenting macrophages interacting with CD8 T cells that consistently segregate with response. We therefore concluded that anti-PD1 agents release the PD1-PDL1 interaction between CD8 T cells and macrophages to promote cytotoxic antitumor activity.

AB - Background & Aims: Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumor mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumor microenvironment (TME) from patients treated with pembrolizumab (KEYNOTE 177 clinical trial) or nivolumab to dissect the cellular and molecular determinants of response to anti- programmed cell death 1 (PD1) immunotherapy. Methods: We selected multiple regions per tumor showing variable T-cell infiltration for a total of 738 regions from 29 patients, divided into discovery and validation cohorts. We performed multiregional whole-exome and RNA sequencing of the tumor cells and integrated these with T-cell receptor sequencing, high-dimensional imaging mass cytometry, detection of programmed death-ligand 1 (PDL1) interaction in situ, multiplexed immunofluorescence, and computational spatial analysis of the TME. Results: In hypermutated CRCs, response to anti-PD1 immunotherapy was not associated with TMB but with high clonality of immunogenic mutations, clonally expanded T cells, low activation of Wnt signaling, deregulation of the interferon gamma pathway, and active immune escape mechanisms. Responsive hypermutated CRCs were also rich in cytotoxic and proliferating PD1 +CD8 T cells interacting with PDL1 + antigen-presenting macrophages. Conclusions: Our study clarified the limits of TMB as a predictor of response of CRC to anti-PD1 immunotherapy. It identified a population of antigen-presenting macrophages interacting with CD8 T cells that consistently segregate with response. We therefore concluded that anti-PD1 agents release the PD1-PDL1 interaction between CD8 T cells and macrophages to promote cytotoxic antitumor activity.

KW - Colorectal cancer

KW - anti-PD1 immunothrepy

KW - Tumour Mutational Burder

KW - Wnt signalling

KW - Interferon Gamma

KW - CD8 T cells

KW - Antigen Presenting Macrophages

KW - Keynote177

UR - http://www.scopus.com/inward/record.url?scp=85111546429&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.06.064

DO - 10.1053/j.gastro.2021.06.064

M3 - Article

SN - 0016-5085

VL - 161

SP - 1179

EP - 1193

JO - Gastroenterology

JF - Gastroenterology

IS - 4

ER -

Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this